Vincerx Pharma Crecimiento futuro
Future controles de criterios 0/6
Vincerx Pharma's earnings are forecast to decline at 21.6% per annum while its annual revenue is expected to grow at 72.4% per year. EPS is expected to grow by 4.8% per annum.
Información clave
-21.6%
Tasa de crecimiento de los beneficios
4.8%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 27.1% |
Tasa de crecimiento de los ingresos | 72.4% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 08 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Aug 21Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 1 | -62 | -43 | N/A | 1 |
12/31/2025 | N/A | -33 | -27 | N/A | 3 |
12/31/2024 | N/A | -31 | -12 | N/A | 3 |
6/30/2024 | N/A | -28 | -28 | -28 | N/A |
3/31/2024 | N/A | -38 | -35 | -35 | N/A |
12/31/2023 | N/A | -40 | -40 | -40 | N/A |
9/30/2023 | N/A | -47 | -46 | -46 | N/A |
6/30/2023 | N/A | -54 | -54 | -54 | N/A |
3/31/2023 | N/A | -61 | -58 | -58 | N/A |
12/31/2022 | N/A | -63 | -60 | -60 | N/A |
9/30/2022 | N/A | -58 | -57 | -57 | N/A |
6/30/2022 | N/A | -66 | -53 | -53 | N/A |
3/31/2022 | N/A | -49 | -45 | -45 | N/A |
12/31/2021 | N/A | -39 | -39 | -33 | N/A |
9/30/2021 | N/A | -49 | -29 | -24 | N/A |
6/30/2021 | N/A | -25 | -19 | -14 | N/A |
3/31/2021 | N/A | -23 | -11 | -6 | N/A |
12/31/2020 | N/A | -17 | -2 | -2 | N/A |
9/30/2020 | N/A | 0 | 0 | 0 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: VINC is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: VINC is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: VINC is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: VINC is forecast to have no revenue next year.
Ingresos de alto crecimiento: VINC is forecast to have no revenue next year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if VINC's Return on Equity is forecast to be high in 3 years time